HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Griffith, B. P. Articles by Bahnson, H. T. Search for Related Content PubMed PubMed Citation Articles by Griffith, B. P. Articles by Bahnson, H. T.

The Journal of Thoracic and Cardiovascular Surgery, Vol 87, 35-42, Copyright © 1984 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Powerful but limited immunosuppression for cardiac transplantation with cyclosporins and low-dose steroid

BP Griffith, RL Hardesty and HT Bahnson

Cyclosporin and low-dose prednisone provide powerful but limited immunosuppression for orthotopic cardiac transplantation. Optimal long- term survival was possible only with rescue therapy using rabbit antithymocyte globulin (RATG) when myocyte necrosis could not be reversed with pulse steroid therapy. The continued absence of rejection following rescue therapy with RATG in six of the last 19 patients is responsible for the improved 79% cumulative survival rate at 9 months compared to the 61% cumulative survival rate at 1 year for the initial 23 patients. The difference is that among the latter group, seven patients had persistent histologic rejection with focal myocyte necrosis which was not reversed with pulse therapy of steroids (hydrocortisone) or an increased dose of maintenance prednisone (30 to 40 mg/day). Three of these seven died of acute rejection within 3 months and four died between 8 and 13 months. Consequently, the cumulative survival rate of these 23 patients at 2 years was 41%. The projected 2 year cumulative survival rate of the 19 patients should not decrease greatly, as new episodes of rejection have not occurred beyond 3 months in either group.

This article has been cited by other articles:

				B. T. Bethea, D. D. Yuh, J. V. Conte, and W. A. Baumgartner Heart Transplantation Card. Surg. Adult, January 1, 2003; 2(2003): 1427 - 1460. [Full Text]

				S. M. Pham, R. L. Kormos, R. J. Landreneau, A. Kawai, I. Gonzalez-Cancel, R. L. Hardesty, B. G. Hattler, and B. P. Griffith Solid Tumors After Heart Transplantation: Lethality of Lung Cancer Ann. Thorac. Surg., December 1, 1995; 60(6): 1623 - 1626. [Abstract] [Full Text]

				W. A. Hall, A. J. Martinez, J. S. Dummer, B. P. Griffith, R. L. Hardesty, H. T. Bahnson, and L. D. Lunsford Central Nervous System Infections in Heart and Heart-Lung Transplant Recipients Arch Neurol, February 1, 1989; 46(2): 173 - 177. [Abstract] [PDF]

				J. C. Baldwin Lung Transplantation JAMA, April 15, 1988; 259(15): 2286 - 2287. [Abstract] [PDF]